Picard Medical Inc. (PMI) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, PMI carries a score of 48 out of 100, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 10/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 7/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the cash-engine pillar is the weakest signal: the source data reports zero ROIC and zero FCF yield, so the rating reflects no demonstrated cash generation at present. The balance-sheet pillar is the strongest, with an Altman Z of 2.5 and a Piotroski F of 6/9, which together describe a financial position that the rating treats as relatively sturdier than its earnings profile. Flow and insider pillars are mid-to-low, indicating limited evidence of conviction from institutional or insider participants. Macro fit at a beta of 1.0 means the stock is assessed as moving in line with the broader market, without a defensive or amplified profile. The verdict implies that, on this framework, the stock's upside case rests on catalysts rather than on current earnings, and that a distribution-warning label signals elevated risk of downside. This analysis is educational and does not constitute personalized financial advice.

Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with cash of $7.5M and debt not reported. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. The balance-sheet pillar is the rating's strongest component, while the absence of reported profitability and cash flow is the principal weakness.

• What is the company's revenue history and business model, given that FY 2025 reports zero revenue and zero net income?
• What was the nature and scope of the 1-for-50 reverse split referenced in market coverage, and how did it affect share count?
• What are the substance and status of the claims referenced in the Johnson Fistel investigation notice?
• What is the company's debt position, given that debt is reported as N/A while Debt/Equity is cited at 0.5?
• What is the source of the cash runway behind the $7.5M cash balance, and what is the implied burn rate?